Athira Pharma Inc Stock Ownership - Who owns Athira Pharma?

Insider buying vs selling

Have Athira Pharma Inc insiders been buying or selling?
Mark WorthingtonGENERAL COUNSEL2024-01-052,412$2.91
Rachel LeningtonChief Operating Officer2024-01-052,412$2.91
Rachel LeningtonCOO AND CDO2024-01-052,412$2.91
Mark James LittonChief Executive Officer2024-01-054,820$2.91
Mark James LittonCEO2024-01-054,820$2.91
Mark WorthingtonGeneral Counsel2024-01-052,412$2.91
Kevin ChurchCHIEF SCIENTIFIC OFFICER2024-01-052,412$2.91
Andrew GengosCFO AND CHIEF BUSINESS OFFICER2024-01-051,208$2.91
Perceptive Advisors LLCDirector2023-12-29163,954$2.38
Perceptive Advisors LLCDirector2023-12-28409,598$2.44

1 of 2

ATHA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ATHA insiders and whales buy or sell their stock.

ATHA Shareholders

What type of owners hold Athira Pharma Inc stock?
Perceptive Advisors LLC14.10%5,402,964$13.72MInstitution
Perceptive Advisors LLC14.10%5,402,964$13.72MInsider
Baker Bros Advisors LP8.23%3,153,807$8.01MInstitution
Joseph Edelman8.13%3,114,805$7.91MInsider
Rtw Investments LP6.96%2,668,913$6.78MInsider
Vanguard Group Inc4.26%1,634,433$4.15MInstitution
Propel Bio Management LLC3.89%1,492,792$3.79MInstitution
Simplify Asset Management Inc3.89%1,492,792$3.79MInstitution
Bml Capital Management LLC2.35%900,000$2.29MInstitution
Tang Capital Management LLC2.22%852,715$2.17MInstitution

1 of 3

ATHA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ATHA56.60%31.41%Net Buying
DBVT39.08%15.37%Net BuyingNet Selling
VTGN38.52%61.48%Net Buying

Athira Pharma Stock Ownership FAQ

Who owns Athira Pharma?

Athira Pharma (NASDAQ: ATHA) is owned by 56.60% institutional shareholders, 31.41% Athira Pharma insiders, and 12.00% retail investors. Perceptive Advisors LLC is the largest individual Athira Pharma shareholder, owning 5.40M shares representing 14.10% of the company. Perceptive Advisors LLC's Athira Pharma shares are currently valued at $13.72M.

If you're new to stock investing, here's how to buy Athira Pharma stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.